Thus,TPMT genotyping can be useful for optimizing 6-MP therapy
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:In this study we aim to determine the genotype distribution and allelefrequencies of common TPMT (*2, *3A, *3B and *3C) polymorphisms inTurkish children with acute leukemia.
📊
Temel Bulgular & Veri:The study population consisted of 169patients aged between 1 and 15 years who were admitted to Losante PediatricHematology and Children’s Hospital with the diagnosis of acute leukemia.Genotyping of TPMT polymorphisms was screened with real-time PCR usingfluorescence melting curve detection analysis.
💡
Sonuç & Katkı:Thus,TPMT genotyping can be useful for optimizing 6-MP therapy
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Abstract
In this study we aim to determine the genotype distribution and allelefrequencies of common TPMT (*2, *3A, *3B and *3C) polymorphisms inTurkish children with acute leukemia. The study population consisted of 169patients aged between 1 and 15 years who were admitted to Losante PediatricHematology and Children’s Hospital with the diagnosis of acute leukemia.Genotyping of TPMT polymorphisms was screened with real-time PCR usingfluorescence melting curve detection analysis. We found that the frequenciesof four allelic variants of TPMT are *2 (238 G>C) (0,0%), *3A (460G>Aand 719A>G) (1.7%), *3B (460G>A) (1,7%) and *3C (719A>G) (2.4%).Frequency of TPMT alleles increases the efficacy of leukemia treatment. Thus,TPMT genotyping can be useful for optimizing 6-MP therapy
🔖
Bu Makaleye Atıf Yap
Kürekçi, E., Akın, D. F., Aşlar-Öner, D., Akar, N. (2022). Frequency of thiopurine S-methyltransferase gene variations in Turkish children with acute leukemia. Turkish Journal of Pediatrics, Cilt: 60 - Sayı: 2, 147–152. https://ajindex.com/articles/613153
Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39
Azimi F, Jafariyan M, Khatami S, Mortazavi Y, Azad M. Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia. Iran J Ped Hematol Oncol 2014; 4: 32-38
Buster EH, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur J Gastroenterol Hepatol 2008; 20: 68-72
Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 22: 7403-7413
McLeod HL, Pritchard SC, Githang’a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9: 773-776
Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006; 46: 317-353
Wells RJ, Woods WG, Buckley JD, et al. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A children cancer group study. J Clin Oncol 1994; 12: 2367-2377
Lennard L, Maddocks J. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol 1983; 35: 15-18
Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879-887
Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30
Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006; 46: 317-353
Wall AM, Rubnitz JE. Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children. Pharmacogenomics J 2003; 3: 128-135
Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-2301
Relling MV, Gardner EE, Sandborn WJ, et al; Clinical Pharma